Answers are grounded in this paper and cite their sources.
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
No takes yet. Share an insight, caveat, or question.
Polsfuß et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: